Clinical Trial Update: Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study of Gazyvaro (obinutuzumab) with low-dose radiotherapy in early-stage follicular lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Gazyvaro (obinutuzumab)

Snippet

Sponsor: Heidelberg University | Conditions: Stage II Grade 1 Follicular Lymphoma, Stage II Grade 2 Follicular Lymphoma | Phase 2 | Status: COMPLETED